BH3 profiling predicts clinical response in a phase II clinical trial of ABT-199 (GDC-0199) in acute myeloid leukemia

被引：3

作者：

Hogdal, Leah ^{[1
]}

Chyla, Brenda ^{[2
]}

McKeegan, Evelyn ^{[2
]}

Leverson, Joel ^{[2
]}

Potluri, Jalaja ^{[2
]}

Falotico, Nancy ^{[2
]}

Ricker, Justin ^{[2
]}

Humerickhouse, Rod ^{[2
]}

Mabry, Mack ^{[2
]}

Foight, Glenna ^{[3
]}

Keating, Amy ^{[3
]}

Galinsky, Ilene ^{[1
]}

Stone, Richard ^{[1
]}

DeAngelo, Daniel ^{[1
]}

Konopleva, Marina ^{[4
]}

Letai, Anthony ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Abbvie Inc, N Chicago, IL USA

[3] MIT, Cambridge, MA 02139 USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

CANCER RESEARCH | 2015年 / 75卷

关键词：

D O I：

10.1158/1538-7445.AM2015-2834

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2834

引用

页数：2

共 50 条

[41] DENDRITIC CELL VACCINATION AS POST-REMISSION THERAPY FOR ACUTE MYELOID LEUKEMIA: RESULTS OF A PILOT PHASE I/II CLINICAL TRIAL
Anguille, S.
Van Tendeloo, V.
Van de Velde, A.
Van Driessche, A.
Vermeulen, K.
Pieters, K.
Nijs, G.
Stein, B.
Smits, E.
Schroyens, W.
Gadisseur, A.
Vrelust, I.
Jorens, P.
Goossens, H.
Price, D.
De Vries, J.
Oji, Y.
Oka, Y.
Sugiyama, H.
Cools, N.
Berneman, Z.
EXPERIMENTAL HEMATOLOGY, 2010, 38 (09) : S36 - S37
[42] Idarubicin and Cytarabine Combined with Clofarabine or Fludarabine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: Interim Result of a Phase II Clinical Trial
Koller, Paul B.
Sasaki, Koji
Ravandi, Farhad
Garcia-Manero, Guillermo
O'Brien, Susan
Cortes, Jorge E.
Kadia, Tapan
Borthakur, Gautam
Pemmaraju, Naveen
Daver, Naval
Chahoud, Jad
Pike, Allison
Brandt, Mark
Pierce, Sherry
Kantarjian, Hagop M.
Jabbour, Elias
BLOOD, 2015, 126 (23)
[43] Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial
Simoes, Catia
Paiva, Bruno
Martinez-Cuadron, David
Bergua, Juan-Miguel
Vives, Susana
Algarra, Lorenzo
Tormo, Mar
Martinez, Pilar
Serrano, Josefina
Herrera, Pilar
Ramos, Fernando
Salamero, Olga
Lavilla, Esperanza
Gil, Cristina
Lopez, Jose-Luis
Vidriales, Maria-Belen
Labrador, Jorge
Falantes, Jose-Francisco
Sayas, Maria-Jose
Ayala, Rosa
Martinez-Lopez, Joaquin
Villar, Sara
Calasanz, Maria-Jose
Prosper, Felipe
San-Miguel, Jesus F.
Sanz, Miguel Angel
Montesinos, Pau
BLOOD ADVANCES, 2021, 5 (03) : 760 - 770
[44] Biomarker-Driven Phase Ib Clinical Trial of OPB-111077 in Acute Myeloid Leukemia Increases Overall Response Rates
Martinez-Lopez, Joaquin
Montesinos, Pau
Sanchez, Pilar Martinez
Gorrochategui, Julian
Rojas, Jose Luis
Primo, Daniel
Bergua, Juan-Miguel
Ayala, Rosa M. M.
Calbacho, Maria
Lopez-Munoz, Nieves
Acuna, Evelyn
Perez-Simon, Jose Antonio
De la Fuente, Adolfo
De Oteyza, Jaime Perez
Rodriguez-Veiga, Rebeca
Boluda, Blanca
Cano, Isabel
Ballesteros, Joan
BLOOD, 2020, 136
[45] Clinical and immunological Activity of WT1 peptide vaccination in patients with acute myeloid leukemia and myelodysplasia: Results of a phase II trial.
Keilholz, Ulrich
Letsch, Anne
Busse, Antonia
Asemissen, Anne M.
Schmittel, Alexander
Hofmann, Wolf K.
Uharek, Lutz
Blau, Igor W.
Thiel, Eckhard
Scheibenbogen, Carmen
BLOOD, 2006, 108 (11) : 171A - 171A
[46] Effectiveness of chemotherapy using bortezomib combined with homoharringtonine and cytarabine in refractory or relapsed acute myeloid leukemia: a phase II, multicenter, prospective clinical trial
Zhang, Chengtao
Gao, Da
Wang, Xiaohong
Sun, Xiuli
Yan, Yan
Yang, Yan
Zhang, Jingjing
Yan, Jinsong
FRONTIERS IN ONCOLOGY, 2023, 13
[47] Clinical and Serologic Interleukin 2 Receptor α Response to Interleukin-2 in CCG-2961, a Ranomized Phase 3 Trial for Pediatric Acute Myeloid Leukemia.
Lange, Beverly
Yang, Richard K.
Gan, Jacek
Hank, Jaqueline A.
Sievers, Eric
Gerbing, Robert
Alonzo, Todd
Sondel, Paul M.
BLOOD, 2008, 112 (11) : 353 - 353
[48] The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, Rosa
Rapado, Inmaculada
Onecha, Esther
Martinez-Cuadron, David
Carreno-Tarragona, Gonzalo
Bergua, Juan Miguel
Vives, Susana
Algarra, Jesus Lorenzo
Tormo, Mar
Martinez, Pilar
Serrano, Josefina
Herrera, Pilar
Ramos, Fernando
Salamero, Olga
Lavilla, Esperanza
Gil, Cristina
Lopez Lorenzo, Jose Luis
Vidriales, Maria Belen
Labrador, Jorge
Falantes, Jose Francisco
Sayas, Maria Jose
Paiva, Bruno
Barragan, Eva
Prosper, Felipe
Sanz, Miguel angel
Martinez-Lopez, Joaquin
Montesinos, Pau
CANCERS, 2021, 13 (10)
[49] PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): A phase II clinical trial.
Stone, RM
Klimek, V
DeAngelo, DJ
Nimer, S
Estey, E
Galinsky, I
Neuberg, D
Yap, A
Fox, EA
Gilliland, DG
Griffin, J
BLOOD, 2002, 100 (11) : 86A - 86A
[50] Phase II Clinical Trial of Alisertib, an Aurora a Kinase Inhibitor, in Combination with Induction Chemotherapy in High-Risk, Untreated Patients with Acute Myeloid Leukemia
Brunner, Andrew M.
Blonquist, Traci M.
DeAngelo, Daniel J.
McMasters, Malgorzata
Winer, Eric S.
Hobbs, Gabriela S.
Amrein, Philip C.
Hock, Hanno
Steensma, David P.
Garcia, Jacqueline S.
Luskin, Marlise R.
Stone, Richard M.
Ballen, Karen K.
Rosenblatt, Jacalyn
Avigan, David E.
McAfee, Steven L.
Moran, Jenna A.
Bergeron, Meghan
Foster, Julia
Bertoli, Christina
McGregor, Kristin
Fishman, Kaitlyn
Macrae, Molly
Burke, Meghan
Behnan, Tanya T.
Som, Tina T.
Ramos, Aura Y.
Vartanian, Megan K.
Nelson, Nicole
Logan, Emma
Story, Jennifer Lombardi
Connolly, Christine
Neuberg, Donna S.
Chen, Yi-Bin
Graubert, Timothy A.
Fathi, Amir T.
BLOOD, 2018, 132

← 1 2 3 4 5 →